Oncolytic Adenovirus Market was valued at USD 115 million in 2024 and is projected to reach USD 310 million by 2034

Oncolytic Adenovirus Market
The Oncolytic Adenovirus Market was valued at USD 115 million in 2024 and is projected to reach USD 310 million by 2034, growing at a CAGR of around 10.4%. Growth is driven by rising demand for gene-modified viral therapies, increasing investment in immuno-oncology, and strong clinical interest in next-generation oncolytic vectors.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71266

Key Market Drivers
• Expanding pipeline of genetically engineered oncolytic adenoviruses for solid tumors.
• Growing integration of viral therapy + immunotherapy combinations.
• Rising incidence of hard-to-treat cancers (glioma, pancreatic, melanoma).
• Increasing clinical trial funding in virotherapy and tumor-selective viral engineering.

Challenges
• Safety and manufacturing complexities of viral therapies.
• High development costs and stringent regulatory pathways.
• Limited commercialized products and small patient population.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71266/oncolytic-adenovirus-market

Market Segmentation
By Application
• Solid tumors (primary segment)
• Hematologic cancers (emerging)

By Therapy Type
• Genetically modified oncolytic adenoviruses
• Non-modified adenoviral vectors
By End User
• Hospitals
• Cancer specialty centers
• Research & clinical trial institutes

By Distribution Channel
• Hospital pharmacies
• Research supply networks

Regional Snapshot
• North America leads due to strong clinical trial activity and advanced immuno-oncology infrastructure.
• Europe shows solid growth supported by government-funded virotherapy research.
• Asia-Pacific is the fastest-growing region with rising biotech investment and expanding oncology programs.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71266

Key Companies
Oncorus, DNAtrix, Sorrento Therapeutics, Lokon Pharma, VCN Biosciences, CG Oncology, Merck (collaborative immuno-oncology programs).

Future Outlook
The market will accelerate as next-gen adenoviral vectors, combination therapies, and personalized viral platforms gain regulatory traction. Increased R&D, better tumor-targeting mechanisms, and scalable viral manufacturing will shape long-term growth.

This report is also available in the following languages : Japanese (腫瘍溶解性アデノウイルス市場), Korean (종양용해성 아데노바이러스 시장), Chinese (溶瘤腺病毒市场), French (Marché des adénovirus oncolytiques), German (Markt für onkolytische Adenoviren), and Italian (Mercato dell'adenovirus oncolitico), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71266

Our More Reports:

Sarcoidosis Market
https://exactitudeconsultancy.com/reports/71350/sarcoidosis-market

Anti-Glomerular Basement Membrane Market
https://exactitudeconsultancy.com/reports/71352/anti-glomerular-basement-membrane-market

Peanut Allergy Market
https://exactitudeconsultancy.com/reports/71354/peanut-allergy-market

Cytomegalovirus (CMV) Infections Market
https://exactitudeconsultancy.com/reports/71356/cytomegalovirus-cmv-infections-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.